Tandem Meetings 2023 | Factors driving the use of consolidative SCT following tisa-cel in CAYA with R/R B-ALL
Kevin McNerney, MD, MSc, Johns Hopkins All Children’s Hospital, St. Petersburg, FL, describes the results of a study exploring current practice patterns around the use of consolidative stem cell transplantation (SCT) following treatment with tisagenlecleucel (tisa-cel) in children and young adults (CAYA) with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). The survey identified that patient factors including high disease burden, chemotherapy refractoriness, and KTM2A rearrangement were associated with a lower likelihood of recommending SCT. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
